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ABSTRACT
Introduction: Pulmonary arterial hypertension
(PAH) and chronic thromboembolic pulmonary
hypertension (CTEPH) are rare, life-threatening
diseases in which chronically elevated pressure
in the pulmonary arteries results in vascular
remodeling and right heart failure. Treatment
goals are to improve patient functioning,
exercise capacity, and symptoms; delay disease
progression; normalize the right ventricular
function; and, ultimately, improve survival.
Therapeutic management centers on the
affected physiologic pathways and includes
endothelin receptor antagonists,
phosphodiesterase-5 inhibitors, and
prostacyclins. Recently, riociguat, a novel
therapeutic agent that stimulates soluble
guanylate cyclase via the nitric oxide pathway,
was approved for the treatment of both PAH
and CTEPH. Clinical trial data show that
riociguat significantly improves exercise
capacity as well as hemodynamic parameters
in PAH/CTEPH.
Methods: We report on the early use of
riociguat at our center—a large, metropolitan
pulmonary hypertension treatment facility that
cares for [250 patients with PAH/CTEPH.
Through our initial clinical experience, we
offer evidence on the benefits of riociguat in
three patients with PAH associated with
different etiologies, symptoms, and treatment
goals.
Results: Overall, patients at our center who
have received riociguat have experienced
clinical benefits, including improvement in
symptomatic and hemodynamic parameters,
increase in 6-min walk distance, and
improvement or stabilization of World Health
Organization functional class. In several cases,
initial response to riociguat has been
encouraging and has helped patients reach
their treatment goals. Riociguat appears to be
well tolerated, with only one patient
experiencing mild, self-limiting side effects.
Conclusion: Novel agents are continuously
being introduced into the PAH/CTEPH
armamentarium, and clinicians must decide
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how best to integrate them into their existing
treatment algorithms. This case series offers
initial evidence from our practice on the
benefits of riociguat in optimizing
hemodynamic and functional parameters.
These benefits have been observed in PAH
associated with different etiologies and
functional status, and in both first-line and
combination use.
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INTRODUCTION
In patients with persistent, severe pulmonary
hypertension, two important differentials to
consider are pulmonary arterial hypertension
(PAH) and chronic thromboembolic pulmonary
hypertension (CTEPH). Both are rare,
life-threatening diseases in which chronically
elevated pressure in the pulmonary arteries
results in vascular remodeling and right heart
failure [1, 2].
PAH is considered idiopathic (IPAH) if all
known associated and predisposing conditions
have been ruled out. Non-IPAH disease may be
heritable or caused by exposure to drugs or
toxins. It is also associated with underlying
comorbidities, such as connective tissue disease
(CTD), certain heart conditions, portal
hypertension, or human immunodeficiency
virus [3].
The precise etiology of CTEPH is undefined,
though the principle cause is believed to be
unresolved pulmonary emboli. Patients with
prothrombotic conditions, such as lupus and
hereditary thrombophilia, may be at higher risk
for CTEPH following a pulmonary embolism
[2].
Hemodynamic testing in PAH/CTEPH
reveals a mean pulmonary arterial pressure
(mPAP) of[25 mmHg at rest, normal left-sided
filling pressures (i.e., pulmonary artery wedge
pressure or left ventricular end-diastolic
pressure B15 mmHg), along with increased
pulmonary vascular resistance (PVR [3 Wood
units) [4]. In cases of impaired right ventricular
(RV) function, there is also decreased
pulmonary arterial (PA) saturation [5].
Elevations in N-terminal pro-brain natriuretic
peptide (NT-proBNP), a biomarker of RV
dysfunction, are also frequently observed.
Symptomatically, patients may present with
decreased exercise tolerance, dyspnea on
exertion (DOE), syncope, chest pain,
palpitations, and edema [5].
Treatment goals inPAH/CTEPHare to improve
World Health Organization functional class
(WHO FC), increase exercise capacity, normalize
RV function, delay disease progression, and
ultimately improve survival [6]. Historically, oral
agents, such as endothelin receptor antagonists
(ERAs) and/or phosphodiesterase-5 inhibitors
(PDE-5is), have been first-line therapies for
patients with a low-risk profile. Patients are
offered add-on therapies for progressive disease.
Prostacyclins are typically reserved for patients
with a high-risk profile, advanced disease, or
disease that has progressed after prior treatment
[7]. Background therapies, suchas anticoagulants,
are important in CTEPH and may also be used in
PAH [2, 8].
Riociguat is the first member of a novel class
of therapeutics called soluble guanylate cyclase
(sGC) stimulators [9–13]. Riociguat has a dual
mode of action: it sensitizes sGC to endogenous
nitric oxide (NO) by stabilizing NO–sGC
binding and also directly stimulates sGC via a
different binding site, independently of NO [11,
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12]. Riociguat restores the NO–sGC–cGMP
pathway and leads to increased generation of
cGMP [11, 12, 14] (Fig. 1). Results from animal
studies have demonstrated that sGC
stimulation and increases in cGMP lead to
vasodilatory, antifibrotic, antiproliferative, and
anti-inflammatory effects [10–12, 14–23].
In the large-scale, phase 3 PATENT-1
(Pulmonary Arterial Hypertension Soluble
Guanylate Cyclase–Stimulator;
ClincalTrials.gov identifier, NCT00810693)
trial, riociguat significantly improved 6-min
walk distance (6MWD) from baseline to week
12 compared with placebo (?30 m vs. -6 m,
respectively) in patients with symptomatic
PAH, as well as those pretreated with ERAs or
(nonintravenous) prostanoids [24, 25].
Riociguat also significantly and consistently
improved a range of secondary endpoints,
including PVR, NT-proBNP, WHO FC, time to
clinical worsening, and Borg dyspnea score
[24].
Fig. 1 The molecular targets, signaling pathways, and modes
of action of approved pulmonary hypertension (PH)
therapies. cAMP cyclic adenosine monophosphate, cGMP
cyclic guanosine monophosphate, ETRA endothelin receptor
A, ETRB endothelin receptor B, IP prostacyclin, NO nitric
oxide, PDE5 phosphodiesterase type 5, PKA phosphate
kinase A, PKG cGMP-dependent protein kinase, sGC
soluble guanylate cyclase. Reprinted from Humbert and
Ghofrani. Thorax. 2015; Thorax doi:10.1136/thoraxjnl-
2015-207170 [online ﬁrst] via Creative Commons Open
Access license: http://creativecommons.org/licenses/by-nc/4.
0/legalcode
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Similar safety and efficacy results were seen
in the phase 3 CHEST-1 (Chronic
Thromboembolic Pulmonary Hypertension
Guanylate Cyclase Stimulator Trial-1;
ClinicalTrials.gov identifier, NCT00855465)
trial in patients with CTEPH—where a 39-m
increase in 6MWD from baseline to week 16 was
seen in patients receiving riociguat compared
with a decrease of 6 m in those receiving
placebo. Riociguat also improved secondary
endpoints, with decreases in PVR, NT-proBNP,
WHO FC, and time to clinical worsening [26].
The following case series reports on the early
use of riociguat at our center—a large
pulmonary hypertension treatment facility in
New York City (NY, USA). We care for
[250 patients with PAH/CTEPH and routinely
use the full armamentarium of PAH therapies.
Through our initial clinical experience, we offer
evidence on the benefits of riociguat in three
patients with PAH associated with different
etiologies, symptoms, and treatment goals. All
procedures followed were in accordance with
the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1964, as revised in
2013. As this was a retrospective de-identified
case series and no identifying details are
discussed in this article, verbal consent only




A 44-year-old man with Sjo¨gren’s syndrome was
seen at our center for pulmonary testing and
evaluation in 2007. He was referred by his
rheumatologist following abnormal
echocardiographic findings, including right
ventricle dilatation. Due to a history of
underlying CTD, the suspicion for associated
PAH (APAH) was high.
Baseline Evaluation
The initial diagnostic work-up included right
heart catheterization (RHC), which revealed
elevated PAP and decreased PA saturation. The
patient complained of DOE and diminished
exercise capacity. His 6MWD upon presentation
was 212 m. The patient was diagnosed with
APAH related to a primary diagnosis of CTD
(Sjo¨gren’s syndrome) and was classified as WHO
FC III.
Therapeutic Management
The patient was initiated on an oral ERA
(bosentan 62.5 mg orally twice daily, increased
after 1 month to 125 mg orally twice daily, per
protocol). An oral PDE-5i (tadalafil 40 mg once
daily) was later added due to marginal clinical
response. Additional therapies included
warfarin 10 mg once daily and concomitant
background medications specific to the
management of Sjo¨gren’s syndrome.
The patient experienced clinical worsening
over 3 years despite being maintained on his
medications. In 2010, following deterioration to
WHO FC IV status, IV epoprostenol (dose
adjusted to 40 ng/kg/min) was added to his
treatment regimen.
In 2011, RHC showed a decrease in mPAP to
40 mmHg from 60 mmHg while on triple
therapy (bosentan, tadalafil, and epoprostenol)
and cardiac index (CI) increase from 2.33 L/
min/m2 to 2.68 L/min/m2. The patient was now
evaluated as WHO FC II.
In February 2013, after two additional years
of stability, the patient requested alternate PAH
medications given the side effects of his current
regimen—namely, lower extremity edema and
nasal congestion. Our treatment team agreed
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with the request and once macitentan became
available he was switched from bosentan to oral
macitentan (at a dose of 10 mg once daily).
Therapeutic Response
Following the switch to macitentan, the patient
reported less nasal congestion and reduced
peripheral edema. His 6MWD improved,
increasing to 430 m from a baseline value of
410 m prior to the switch to macitentan;
however, he still complained of reduced
exercise tolerance. The decision was made to
transition him from tadalafil. This decision was
based on the favorable symptomatic results seen
with riociguat at our center as well as the
potential antifibrotic effects associated with
riociguat [9, 10].
No protocol currently exists for transitioning
patients from a PDE-5i, but as the concomitant
use of riociguat and PDE-5i’s is contraindicated
we opted for a 2-day washout period from
tadalafil. The patient was started on a riociguat
dosage of 1 mg three times daily, and titrated by
0.5 mg every 2 weeks to the maximum dosage
of 2.5 mg three times daily. The patient was also
maintained on his current doses of macitentan
and IV epoprostenol.
Both the transition to riociguat and the
titration to maximum therapeutic dosage were
well tolerated. The patient initially reported
moderate headaches (5/10 severity),
successfully treated with oral acetaminophen.
After 2 weeks, the headaches spontaneously
resolved, and no further treatment was
necessary.
Six months after starting therapy with
riociguat, the patient’s 6MWD increased to
480 m and FC has remained stable (WHO FC
II). Subjectively, the patient reported significant
improvement in his PAH symptoms, notably in
the area of exercise tolerance. Further
assessment showed, essentially, normalization
of the patient’s hemodynamics at 9-month
follow-up on a triple combination of
epoprostenol, macitentan, and riociguat—with
a stable PA saturation of 69%, decreased mPAP
of 23 mmHg, increased CI of 3.13 L/min/m2,
and decreased PVR of 2.71 Wood units.
Case 2
Referral Pathway
A 65-year-old woman with a 5-year history of
scleroderma/CREST syndrome was first
evaluated at our center in 2011. She was
referred by her cardiologist after abnormal
echocardiographic findings [resting RV systolic
pressure (RVSP) of 71 mm Hg], and complaints
of excessive fatigue, intermittent chest pressure,
and palpitations. The patient’s history of
underlying CTD raised the possibility of an
APAH diagnosis.
Baseline Evaluation
Baseline echocardiograph showed normal right-
and left-ventricle size and function with mild
mitral regurgitation and an RVSP of 47 mm Hg.
RHC confirmed the diagnosis of APAH with an
mPAP of 30 mmHg, PA wedge pressure of
8 mmHg, and CI of 2.83 L/min/m2. Her
6MWD was 213 m. The patient was diagnosed
with WHO FC Class III APAH related to
scleroderma. Prior to initiation of therapy, she
was lost to follow-up.
In 2014, the patient was readmitted with
worsening symptoms characterized by
decreased exercise capacity for 1 month,
culminating in an inability to get out of bed.
Further examination revealed atrial flutter,
elevated liver enzymes, and acute kidney
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injury likely due to cardio-renal syndrome. After
undergoing cardiac rate stabilization and
hemodialysis repeat echocardiogram and RHC
were performed. Results showed an increased
mPAP of 35 mmHg, and a decreased PA
saturation of 46%, while echocardiogram
showed RV dilatation, and hypokinesis. She
was classified as having advanced WHO FC III
PAH.
Therapeutic Management
Riociguat was chosen as a first-line treatment
based on its therapeutic efficacy [10, 11] and
potential antifibrotic effects [11]. An ERA was
not chosen due to the potential for edema/fluid
overload and further liver enzyme elevation.
The patient was started on riociguat 1 mg three
times daily and titrated to 2.0 mg three times
daily.
Therapeutic Response
The patient returned for evaluation 4 weeks
after starting riociguat, at which time her
6MWD had increased to 365 m. She reported
improvement in DOE allowing her to climb five
flights of stairs when her building’s elevator was
not working. This rapid functional
improvement was impressive given the 2.0 mg
three times daily dose—less than the maximal
dose of 2.5 mg. The patient denied experiencing
any side effects from therapy with riociguat.
The patient returned for follow-up
evaluation after 10 weeks and stated that her
exercise capacity had continued to improve.
Echocardiography revealed normal RV size and
function. Although the patient’s RVSP had
increased to 65 mmHg, we considered the
normalization of RV function to be a better
indicator of therapeutic response. Her 6MWD
was maintained at 365 m. Her symptoms and
exercise tolerance were consistent with FC
improvement to WHO II.
Case 3
Referral Pathway
A 51-year-old man was first evaluated at our
center in 2013. He was referred by his primary
medical doctor based on echocardiographic
findings of severe RA and RV dilatation and
severe RV dysfunction, septal flattening, and
symptomatic complaints of progressive DOE
associated with palpitations that were relieved
by rest.
Baseline Evaluation
Baseline echocardiograph showed septal
flattening consistent with RV pressure
overload; RHC confirmed the presence of
severe PAH associated with significant RV
dysfunction. The patient’s NT-proBNP level
was 385 pg/mL and his 6MWD was 426 m.
The patient was diagnosed with WHO FC III
IPAH. Although his 6MWD was favorable, his
low CI (1.66 L/min/m2), relatively low PA
saturation (52%), and echocardiographic
stigmata of poor prognosis prompted our team
to offer continuous parenteral prostacyclin
therapy, which he adamantly refused. As an
alternative, he was started on combination
therapy in rapid succession.
Therapeutic Management
The decision was made to first start the patient
on an ERA. Macitentan was selected given its
favorable long-term data on morbidity and
mortality [27]. The patient was started on a
dose of 10 mg once daily, along with
background therapy of furosemide 40 mg once
daily and potassium chloride 20 mEq once
daily.
Therapeutic Response
The patient returned 2 weeks after starting
macitentan. He reported mild symptomatic
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improvement, including greater energy and
decreased DOE. At 6 weeks, his 6MWD had
increased slightly to 457 m from a baseline of
426 m and his FC remained unchanged. While
his NT-proBNP level had decreased to 183 pg/
mL, it was still nearly double the upper limits of
normal (limits of normal 0–100 pg/mL).
Riociguat was then added to the treatment
regimen based on its clinical efficacy data [9] and
its theoretical mechanistic advantage over
PDE-5is in this patient with chronically
elevated NT-proBNP and persistent FC III
symptoms [10, 11]. The patient was started on
riociguat 1 mg three times daily and dose
adjusted to the maximum therapeutic dosage
of 2.5 mg three times daily.
During the 6-month evaluation on
combination therapy, the patient reported
more energy and less DOE. His symptoms were
classified as FC II and his 6MWD increased to
495 m. NT-proBNP levels at his 6-month
follow-up showed normalization to 31.5 pg/
mL. The patient denied any side effects from
therapy with riociguat.
After 9 months of combination therapy,
repeat echocardiographic still showed RV
dilatation, but only a mild–moderate degree of
RV dysfunction. A repeat RHC 1 month later
confirmed improved RV function, as well as an
increase in PA saturation to 64% and an
increase in CI to 2.18 L/min/m2.
The patient is responding well to
combination therapy, with subjective and
objective improvement noted since the
addition of riociguat. Given his continued RV
dysfunction and a relatively low CI, our team is
considering the addition of inhaled or oral
prostacyclin therapy.
DISCUSSION
Recent clinical guidelines from the European
Society of Cardiology (ESC) and the European
Respiratory Society (ERS) have included
riociguat as initial therapy with grade IB
recommendation for patients with WHO FC
II–III PAH [28]. Additional consensus-based
guidelines recommended riociguat as
monotherapy for treatment-naı¨ve WHO FC
II–III patients (grade CB) and as add-on
therapy in WHO FC III–IV patients currently
on stable doses of ERAs or inhaled prostanoids
(grade CB) [29]. For WHO FC III patients whose
clinical status is unacceptable despite
PAH-monotherapy, addition of a second class
of PAH therapy is warranted. No algorithm
currently exists for its use in the treatment of
CTEPH. Limited guidance is available on
agent-specific PAH combination therapy due
to a lack of comparative effectiveness data [28,
29].
All three patients reported in our series’
presented as WHO FC III for which
monotherapy with an ERA, PDE-5i, or sGC
stimulator is recommended.
There are no formal agent-specific guidelines
for add on or switching therapies and as such,
evidence-based guidance was lacking for
transition from a PDE-5i to riociguat while
simultaneously receiving macitentan and IV
epoprostenol. Based on the pharmacokinetics
of tadalafil, a 2-day washout period was chosen
and riociguat was successfully titrated [30].
Riociguat was chosen over tadalafil based on
the antifibrotic properties it has exhibited in
preclinical studies and their potential benefit in
a patient presenting with concomitant PAH and
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CTD [21–23]. The first patient had a remarkable
therapeutic response of hemodynamic
normalization on triple therapy that included
intravenous epoprostenol. However,
hemodynamic normalization was only
achieved after bosentan was changed to a
newer generation ERA, and tadalafil switched
to riociguat. The effect of macitentan–riociguat
combination therapy was not examined in the
PATENT-1 trial (where the ERA used for
background therapy was bosentan).
There are currently no effective means of
determining which patients may benefit from
specific agents, and as such, familiarity with
individual patient history is critical when
managing advanced disease and establishing
optimal pharmacotherapy for PAH [28, 29]. Our
experience with a WHO FC III patient with
underlying CTD, edema, and liver enzyme
elevation suggests that riociguat represents an
important first-line option for patients with an
aggressive disease course who are not
appropriate for ERAs due to risks of adverse
events. However, it is critical that these patients
be evaluated at an experienced center capable of
diagnosing and managing patients with PAH
[28, 29].
New large-scale trials have produced data on
both long-term outcomes and the safety and
efficacy of new combination regimens.
Historically, PAH medications have been used
in combination in an add-on fashion, as
dictated by the goal-directed therapy principle:
therapy is reassessed every 3 to 6 months and
new treatment agents are added if patients do
not achieve certain clinical and hemodynamic
goals [8]. However, in the modern era, this
approach may change to concomitant
combination therapy upfront from the
moment of diagnosis, as supported by recently
published findings from the large-scale
AMBITION study (A Randomized,
Double-Blind, Multicenter Study of First-Line
Combination Therapy With AMBrIsentan and
Tadalafil in Patients With Pulmonary Arterial
HypertensION; ClinicalTrials.gov identifier,
NCT01178073) and recommended in the
recently updated ESC/ERS guidelines [28]. The
AMBITION study has shown that first-line
combination therapy in PAH improves clinical
outcomes over monotherapy [31].
It has been our general practice to be
assertive with early combination therapy in
patients with severe PAH as evidenced by our
decision to initiate macitentan and riociguat
combination therapy in a patient who refused
parenteral prostacyclin therapy. As his PAH was
rapidly progressing, riociguat was chosen over a
PDE-5i due to its novel action on the NO
pathway [11, 12]. To date, the rapid,
sequential addition of riociguat to an ERA to
enhance treatment response has not been
studied in clinical trials. However, we offer
evidence that a patient with New York Heart
Association (NYHA) FC III symptoms can
achieve significant functional and
hemodynamic improvements with this
regimen, despite evidence of severe PAH
disease on echocardiogram and RHC. As the
patient ultimately showed significant
improvement, we feel aggressive oral
combination therapy may be suitable for
certain patients provided close follow-up and
monitoring.
CONCLUSION
Riociguat, a novel agent that acts via the NO
pathway, was approved in the United States in
2013 for the treatment of both PAH and CTEPH.
As a large, metropolitan PAH/CTEPH treatment
center actively involved in research, our site was
an early adopter of riociguat. This case series
offers initial evidence from our practice on
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benefits of riociguat in optimizing
hemodynamic and functional parameters.
Importantly, these benefits have been observed
in PAH associated with different etiologies and
functional status, as well as in both first-line use
and combination use.
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